Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $31.2 million.

  • United Therapeutics' Change in Accured Expenses fell 545.45% to $31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.7 million, marking a year-over-year increase of 5079.79%. This contributed to the annual value of $42.7 million for FY2024, which is 2521.89% down from last year.
  • According to the latest figures from Q3 2025, United Therapeutics' Change in Accured Expenses is $31.2 million, which was down 545.45% from $46.1 million recorded in Q2 2025.
  • United Therapeutics' 5-year Change in Accured Expenses high stood at $46.1 million for Q2 2025, and its period low was -$34.5 million during Q4 2021.
  • Its 5-year average for Change in Accured Expenses is $10.9 million, with a median of $19.8 million in 2021.
  • In the last 5 years, United Therapeutics' Change in Accured Expenses tumbled by 42242.99% in 2021 and then surged by 12637.68% in 2022.
  • Over the past 5 years, United Therapeutics' Change in Accured Expenses (Quarter) stood at -$34.5 million in 2021, then skyrocketed by 126.38% to $9.1 million in 2022, then plummeted by 353.85% to -$23.1 million in 2023, then rose by 22.08% to -$18.0 million in 2024, then surged by 273.33% to $31.2 million in 2025.
  • Its last three reported values are $31.2 million in Q3 2025, $46.1 million for Q2 2025, and -$2.6 million during Q1 2025.